Samuel D. Waksal is not letting his past stand in the way of his future.

The former chief executive of the biotechnology company ImClone Systems, Mr. Waksal spent five years in federal prison after admitting to insider stock trading and other crimes.

Now, less than two years after regaining his freedom, Mr. Waksal, 63, is mounting an audacious effort at redemption, again in biotechnology.

Call it ImClone II, only bigger, broader and faster.

ImClone took two decades before its first drug came to market, the typical biotechnology development route. But Mr. Waksal says his new venture, Kadmon Pharmaceuticals, will be “a fully integrated biopharmaceutical company from the get-go,” replete with everything, including its own research and products on the market or in clinical trials that it acquires from others.

“You’ll see a company that next year will be doing significant revenues in a growth area, with earnings, probably five Phase 3 programs and a couple of Phase 2 products,” Mr. Waksal said Sunday in a telephone interview. Phase 3 and Phase 2 are the late and middle stages, respectively, of clinical trials.

Several of Mr. Waksal’s former colleagues from ImClone have joined him at Kadmon, a name from kabbalah, the Jewish mystical movement. He even looked into leasing the Lower Manhattan headquarters ImClone is vacating.

Kadmon, which will focus on cancer, infections and autoimmune diseases, has started to make deals. On Monday it is expected to announce it has licensed an experimental hepatitis C drug from Valeant Pharmaceuticals International, a person close to the transaction said. That follows the disclosure last week that it had acquired Three Rivers Pharmaceuticals, a Pennsylvania company specializing in hepatitis drugs.

Kadmon circulated a private placement memorandum in February to raise $50 million to $175 million. As of July, it had raised $10.8 million from 26 investors, a filing with the Securities and Exchange Commission said.

But David Pitts, a spokesman for Kadmon, said that other debt and equity offerings had raised more than $200 million, with the biggest investor being SBI Holdings of Japan. That indicates at least some investors are willing to look beyond Mr. Waksal’s past. For many investors, “there are few judgments beyond whether you made me money,” said Samuel D. Isaly, managing partner at OrbiMed Advisors, a big investor in biotech companies that was not asked to invest in Kadmon. “Sam Waksal made a lot of people a lot of money with ImClone.”

Mr. Waksal led ImClone as it developed the cancer drug Erbitux, which was approved in 2004, after he had gone to prison. In 2008, Eli Lilly & Company acquired ImClone for $6.5 billion.

One investor in Kadmon, who also sits on its board, said Mr. Waksal’s energy and his acumen in spotting promising drugs far outweigh his past problems.

“He is irrepressible,” said this investor, who spoke on the condition that she not be named because her company has a policy against being quoted in the media. “I don’t think what happened to Sam in the past is going to have a negative effect on my investment in this business.”

Yet some biotech investors said they were wary of putting money into Mr. Waksal’s new company, and others said their clients would not allow it.

“The state of Oregon is one of our investors,” said Mr. Isaly of OrbiMed. “They don’t explicitly tell us you can’t invest with felons, but we would know how they feel.”

Mr. Waksal, who earned a doctorate in immunology, is charming to the point of being seductive. He was a fixture in New York social circles, befriending celebrities and dating many women, including Alexis Stewart, daughter of his friend Martha Stewart. He lived in a spacious SoHo loft with millions of dollars in art, where he hosted extravagant parties and intellectual salons attended by leading lights in literature, art and science.

That started to come undone in December 2001, when Mr. Waksal got word that the Food and Drug Administration was not going to approve Erbitux. Before the company announced the news, Mr. Waksal alerted relatives to sell their ImClone stock and tried to sell some of his. Martha Stewart sold her ImClone shares and was given a five-month prison sentence and five months of home confinement for lying to federal investigators about it.

Mr. Waksal pleaded guilty to securities fraud bank fraud, perjury, obstruction of justice and conspiracy. He is prohibited by a settlement with the S.E.C. from serving as an officer or director in a publicly traded company.

While Mr. Waksal says he retained some of his wealth — he would not comment on whether he had made money from stock options when ImClone was sold — he lives less flamboyantly now. His home is one floor of a town house off Fifth Avenue, and he generally keeps out of gossip columns.

“I’m far more circumspect in every single thing I do in life,” he said.

“He hadn’t changed,” said a prospective investor who met with Mr. Waksal and spoke on the condition of anonymity to retain relations with him. “He was spinning big stories about big money, big deals.”

Another prospective investor said Mr. Waksal had told him that Carl C. Icahn, the billionaire who is a friend of Mr. Waksal and had invested in ImClone, had committed $30 million to Kadmon. Marc Weitzen, a lawyer for the investor, said Mr. Icahn had evaluated Kadmon but “decided to pass.”

The private placement memorandum circulated in February said Kadmon had “a simple yet revolutionary plan for creating the pre-eminent 21st century biopharmaceutical company.”

Whether Mr. Waksal’s comments will prove to be hyperbole or fulfilled ambitions may depend on acquisition acumen. In its first big deal, Kadmon announced last Monday that it had acquired privately held Three Rivers for more than $100 million.

Three Rivers, whose main products are drugs for hepatitis C, is meant to be the commercial base of Kadmon, its revenues helping to defray the cost of developing new drugs.

The deal, an investor familiar with the structure said, is highly leveraged, to the extent that Three Rivers’ earnings might not be sufficient to cover the debt. But Mr. Waksal is betting that sales will soar because new pills being developed by other companies will make treatment more effective, enticing more people with hepatitis C to be treated.

“The hep C market is going to undergo a real sea change next year,” Mr. Waksal said. Three Rivers has a proprietary form of the drug ribavirin that requires two pills a day, instead of the standard six to eight. Even with new drugs coming, ribavirin will remain a mainstay of treatment.

In fact, Mr. Waksal is increasing that bet. On Monday, Kadmon is expected to announce that it has obtained exclusive worldwide rights to taribavirin, a form of ribavirin that may have fewer side effects. Kadmon is paying $5 million initially, with other payments possible later, to Valeant Pharmaceuticals, which has been testing the drug in clinical trials, according to the person close the transaction. Valeant will pay $7.5 million for rights to sell Kadmon’s ribavirin in Eastern Europe.

Kadmon has bought a tiny company started by Princeton professors that has a way to measure cell metabolism. Influencing a cell’s use of nutrients is emerging as a novel way to treat cancer and infectious diseases.

It has acquired a cancer drug based on Chinese medicine developed at Yale and by a company called PhytoCeutica. It has also acquired rights to a cancer drug, XL647, initially developed by Exelixis, from an investment firm called Symphony Capital.

Drugs picked up on the cheap from other companies are not always the best drugs.

But the investor on Kadmon’s board said the company’s pipeline is “like a puzzle that fits together perfectly,” so the drugs being acquired have more value in Kadmon’s portfolio than they would elsewhere. For instance, two cancer drugs might be used together for a greater effect.

Richard C. Mulligan, a professor of genetics at Harvard and a close friend of Mr. Waksal, said in an interview that he was talking to Harvard about taking a leave so he could be in charge of science at Kadmon. “I’m excited about the venture, and I do want to participate, and it’s very, very likely that I will,” he said.

Mr. Waksal said he wanted to learn from his mistakes.

“We’re meant to use every single experience in our lives to move forward,” he said. “Because there was that interregnum in my life, I have more of an emphasis to do it very well, without tarnishing, this go-around.”

3 and 16 March 1998: Link to original sources on Echelon 2 February 1998 Source: http://206.13.40.11/1996/dec/echelon.html Thanks to IB EXPOSING THE GLOBAL SURVEILLANCE SYSTEM by Nicky Hager This article is reprinted with the permission of CAQ [to Ham Radio Online] (CovertAction Quarterly). CAQ subscription information follows the article. This article appea […]

News American Forces Press Service E-Mail A Copy | Printer Friendly | Latest News News Article Army Research Grant to Explore Communication Through Brain Waves By Donna Miles American Forces Press Service The 1982 Clint Eastwood thriller “Firefox” seemed like the ultimate military science fiction story: A former Vietnam War pilot steals a state-of-the-art […]

You Carry the Cure In Your Own Heart Emotional abuse of children can lead, in adulthood, to addiction, rage, a severely damaged sense of self and an inability to truly bond with others. But—if it happened to you—there is a way out. by Andrew Vachss Originally published in Parade Magazine, August 28, 1994 The attorney […]

February 22, 1987 A debate has developed over whether the space weapon envisioned by the Reagan Administration for the first phase of its plan for a defense against missiles could strike offensively at targets in orbit and on earth. Scientists and space experts who are critical of the ”Star Wars” plan say the weapon’s potential […]

Medical News and Perspectives | July 23/30, 2003 JAMA. 2003;290(4):449-450. doi:10.1001/jama.290.4.449 The United Kingdom (UK) has granted a license to Roslin Institute, Edinburgh, Scotland, to create human embryos for stem cell research via parthenogenesis, a “virgin birth” technique that jolts oocytes into a fertilized state without sperm. The license also […]

CIA MIND CONTROL AT STANFORD RESEARCH INSTITUTE By Alex Constantine December 1996 Concrete evidence that electronic mind control was an object of study at SRI was exposed by the Washington Post on August 7, 1977: “When the Navy awarded a contract to the Institute, the scientific assistant to the Secretary of the Navy, Dr. Sam […]

CIA-Initiated Remote Viewing At Stanford Research Institute by H. E. Puthoff, Ph.D. Institute for Advanced Studies at Austin 4030 Braker Lane W., #300 Austin, Texas 78759-5329 Abstract – In July 1995 the CIA declassified, and approved for release, documents revealing its sponsorship in the 1970s of a program at Stanford Research Institute in Menlo Park, […] […]

IMAGINE a presidential candidate who spoke with blunt honesty about American problems, dwelling on measures by which the United States lags its economic peers. What might this mythical candidate talk about on the stump? He might vow to turn around the dismal statistics on child poverty, declaring it an outrage that of the 35 most […]

Part spy, part tycoon, Edwin P. Wilson lived large. He claimed to own 100 corporations in the United States and Europe, many of them real and many of them shells. He had an apartment in Geneva; a hunting lodge in England; a seaside villa in Tripoli, Libya; a town house in Washington; and real estate […]

Greece said on Friday it would replace the board of its independent statistics service (ELSTAT) after two members resigned and another was quoted as alleging that 2009 deficit data had been artificially inflated. It said ELSTAT chief Andreas Georgiou would keep his post. The upward revision of Greece’s budget deficit in 2009 to 15.4 percent […]

With at least the tacit backing of U.S. Central Intelligence Agency officials, operatives linked to anti-Castro terrorists introduced African swine fever virus into Cuba in 1971. Six weeks later an outbreak of the disease forced the slaughter of 500,000 pigs to prevent a nationwide animal epidemic. A U.S. intelligence source told Newsday last week he […]

The Central Intelligence Agency took no action after learning the pseudonym and whereabouts of the fugitive Holocaust administrator Adolf Eichmann in 1958, according to C.I.A. documents released Tuesday that shed new light on the spy agency’s use of former Nazis as informants after World War II. The C.I.A. was told by West German intelligence that […]

Mere Tinkering With a Bad Program The Obama administration announced last month plans to repair Secure Communities, the program that compels state and local police to join its wide and expanding hunt for illegal immigrants. From now on, when illegal immigrants are stopped for traffic violations by local police, Immigration and Customs Enforcement will consid […]

Brigitte Lahaie, covered up for the moment, in Jean Rollin’s “Fascination.” The movies have their outsider artists too, filmmakers who work away from the established centers and financial structures, often laboring in blissful ignorance of academic technique. A disproportionate number of these directors work in horror films, for reasons that probably have to […]

ce399. 2012 1 Corinthians 13 (NIV) 1 If I speak in the tongues[a] of men or of angels, but do not have love, I am only a resounding gong or a clanging cymbal. 2 If I have the gift of prophecy and can fathom all mysteries and all knowledge, and if I have a faith […]

Pity not the fallen! I never knew them. I am not for them. I console not: I hate the consoled & the consoler. I am unique & conqueror. I am not of the slaves that perish. Be they damned & dead! Amen. http://hermetic.com/legis/ccxx/chapter-ii.html

The Voices in Philip K. Dick’s Head By CHARLES PLATT THE EXEGESIS OF PHILIP K. DICK Edited by Pamela Jackson, Jonathan Lethem and Erik Davis. Illustrated. 944 pp. Houghton Mifflin Harcourt. $40. In 1979, I visited Philip K. Dick for a profile I was writing. In a modest apartment he shared with dusty stacks of […]

A woman with her child at a cholera treatment centre (14 Dec 2010) There have been calls for better public health information throughout the epidemic Continue reading the main story Rebuilding Haiti * The rubble problem * Progress: In graphics * An aid worker’s view * In pictures: Wolfgang Tillmans Voodoo priests in Haiti are […]

Is Madonna Jewish? The material girl’s professed faith has little to do with classical Jewish mysticismIn 1941, Gershom Scholem published “Major Trends in Jewish Mysticism,” a groundbreaking study of Kabbalah’s murky origins, complicated texts and arcane ideas. Scholem, who died in 1982, concluded the book with a vague prediction: “Under what aspects this in […]

Angels Doing Time “The world will end…the mechanical will have Americanized us to such a degree, progress will have atrophied the entire spiritual part within us, [that we will] die by that we had thought we could live by. [We will be destroyed]… by the abasement of the heart.” – Charles Baudelaire. April 9, 1821 […]

In a fiery speech justifying her decision to nationalize the oil company YPF, Argentina’s president, Cristina Fernández de Kirchner, cited her admiration for Petrobras, Brazil’s state-controlled oil giant, and other state oil companies in Latin America. But here in Brazil, Latin America’s rising oil power, and elsewhere in the region, financial experts greet […]

Modes of Governance in Neo-Liberal Capitalism: An Introduction Hai Ren [1] Neo-liberal capitalism – which has become not necessarily better or more advanced but certainly more complicated and more dominant in contemporary human lives – signals a significant departure from liberal capitalism. Under the guise of liberal capitalism, the Eurocentric norm of stat […]